human bmp6 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
95
Structured Review
R&D Systems
human bmp6
Human Bmp6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 113 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+bmp6+protein/Recombinant+Human+BMP-6+Protein/us12612452-522-3-6
Average 95 stars, based on 113 article reviews
Human Bmp6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 113 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+bmp6+protein/Recombinant+Human+BMP-6+Protein/us12612452-522-3-6
Average 95 stars, based on 113 article reviews
human bmp6 - by Bioz Stars,
2026-08
95/100 stars
![BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in control pulmonary arterial endothelial cells (PAECs) in vitro. A , Representative immunofluorescent staining of PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI; nuclei). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show CD31 and SM22α intensity quantification (n=3). B , sST2 , ST2L , CTGF , and PAI-1 gene expressions in PAECs after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; technical replicates [t.n.]=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAECs after 3-hour stimulation with BMP4 (50 ng/mL), <t>BMP6</t> (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; * P <0.05, ** P <0.01, and **** P <0.0001. Data are shown as mean±SD.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_2782/pmc12822782/pmc12822782__hyp-83-e24916-g002.jpg)
![BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in pulmonary arterial endothelial cells (PAECs) from patients with pulmonary arterial hypertension (PAH) in vitro. A , Representative immunofluorescent staining of PAH PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show quantification of CD31 and SM22α intensity (technical replicates [t.n.]=3). B , sST2 , ST2L , CTGF , and Pai-1 gene expressions in PAH PAECs s after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; t.n.=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAH PAECs after 3-hour stimulation with BMP4 (50 ng/mL), BMP6 (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; P <0.05, * P <0.01, ** P <0.001, and *** P <0.0001. Data are shown as mean±SD.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_2782/pmc12822782/pmc12822782__hyp-83-e24916-g005.jpg)